Drugs / MSC(AT)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06722105 | Dec 2024 → Apr 2026 overdue | systemic sclerosis | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSC(AT) | “The increasing use of MSC, harvested from bone marrow (MSC(M)), adipose tissue (MSC(AT)), or umbilical cord (MSC(UC)) in a variety of indications, provides consistent evidence...” NCT06722105 ↗ |
| Modality | Cell therapy | “Mesenchymal stromal cells (MSC) are multipotent cells” NCT06722105 ↗ |
| Route | Other | “MSC(AT) (2x10\^6 cells/kg) injection at M0” NCT06722105 ↗ |